How does DSIP map to the hallmarks of aging?

DSIP's longevity relevance maps to specific hallmarks based on its mechanism. Mechanism remains incompletely characterised. Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier. For users tracking healthspan-relevant biomarkers across cycles, the relevant endpoints are determined by which hallmark the compound primarily targets — telomere maintenance, senescence modulation, mitochondrial biogenesis, autophagy induction, inflammaging, or epigenetic clock effects. The framework above identifies the dominant contribution.

What class of compound is DSIP?

DSIP is classified as a Neuropeptide (sleep). Within this class, alternative names and analogues include Delta Sleep-Inducing Peptide. The class-level pharmacology shapes both the clinical applications and the safety profile; the longevity / hallmarks of aging literature treats DSIP alongside its class peers when evaluating relative merits.

What is the standard dosing protocol for DSIP?

Conventional DSIP dosing is 100-500 mcg 1x daily before sleep via subq/intranasal. For healthspan and biological-age use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Standard cycle for DSIP is 8–12 weeks of 1x daily before sleep 100-500 mcg dosing via subq/intranasal, followed by a 4 week complete off-period. The off-period is calibrated to DSIP's ~7 min plasma; CNS effects longer half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

How should DSIP be stored and reconstituted?

Lyophilised DSIP stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

Home/ Compounds/ DSIP

DSIP

Longevity

Healthspan-relevant evaluation of DSIP starts with mapping its mechanism to the hallmarks of aging and asking which of the nine hallmarks its primary pharmacology engages. Mechanism remains incompletely characterised Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier.. The ~7 min plasma; CNS effects longer pharmacokinetic profile, the cycle-based 100-500 mcg 1x daily before sleep dosing pattern, and the longevity-specific stack partners on adjacent hallmarks together produce the framework documented below.

Longevity / Hallmarks of Aging Applications

Mitochondrial BiogenesisCellular ReprogrammingSenescence ModulationStem Cell FunctionTelomere Support

Key Takeaways

Longevity lens: DSIP maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: Mechanism remains incompletely characterised.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 100-500 mcg 1x daily before sleep dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

Mechanism remains incompletely characterised. Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier. Healthspan-relevant interpretation of this mechanism asks which biomarkers move, in which direction, on what timescale. The subsections below cover the hallmark mapping, cellular and transcriptional effects, biomarker tracking, and the cycle structure favoured in longevity-research protocols for DSIP.

Mapping to the hallmarks of aging

DSIP's longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. Mechanism remains incompletely characterised. Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier. This places its dominant contribution in the integrative hallmarks (systemic and inflammatory) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.

Healthspan markers and biological age

For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after DSIP cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.

Cellular reprogramming and gene expression

Where DSIP has measurable effects on transcriptional programmes, the direction of effect tends to be toward younger phenotypes rather than away from them. This signature — partial reversal of age-associated expression changes — is what distinguishes a true longevity-relevant compound from a symptomatic one. The signal strength varies, but the direction is what longevity researchers track.

Longevity / Hallmarks of Aging Applications

Senescence Modulation

For senescence modulation as a longevity-relevant endpoint, DSIP is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Autophagy Induction

DSIP's contribution to autophagy induction as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Telomere Support

Telomere Support maps to one of the hallmarks of aging and is one of the dimensions on which DSIP is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Mitochondrial Biogenesis

For mitochondrial biogenesis as a longevity-relevant endpoint, DSIP is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100-500 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60-500 mcg	4–6 weeks initial cycle
Longevity focus	SubQ	100-500 mcg	1x daily before sleep
Maintenance phase	SubQ	70-500 mcg	Ongoing with periodic pauses

Dose timing for DSIP is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

DSIP stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

DSIP + Epithalon: Identified by Khavinson in St. Pairs naturally with DSIP's mechanism in longevity / hallmarks of aging protocols.
DSIP + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with DSIP's mechanism in longevity / hallmarks of aging protocols.
DSIP + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with DSIP's mechanism in longevity / hallmarks of aging protocols.
DSIP + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with DSIP's mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Preclinical + small human series

Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants.

Lens-specific safety considerations for longevity / hallmarks of aging use of DSIP: Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

DSIP — characterisation and effects on sleep

PMID 6324019

Supporting

DSIP and HPA axis modulation

PMID 20066503

DSIP vs Related Peptides

Compound	Profile	Onset	Best For
DSIP	Neuropeptide (sleep)	~7 min plasma; CNS effects longer	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Best stack pairing for longevity?

Layered protocols cover multiple hallmarks of aging simultaneously: pineal/telomere (epithalon), thymic/immune (thymalin), mitochondrial (MOTS-c, NAD+), ECM and gene expression (GHK-Cu), and metabolic flexibility (metformin-class or GLP-1-class as appropriate). DSIP contributes to its specific hallmark layer in this multi-component framework.

Cycle-based or continuous dosing for longevity?

Longevity-research convention favours cycle-based and pulsatile interventions over indefinite continuous administration. Hormetic stimulation produces stronger systems-biology effects than sustained agonism for most longevity-relevant endpoints. DSIP fits this framework with cycle lengths typical for its compound class.

How do I know if DSIP is working?

Track outcome metrics that match the compound's primary mechanism: epigenetic age (DNA methylation panels), inflammatory markers (hsCRP, IL-6), metabolic flexibility (HbA1c, fasting insulin, HOMA-IR), body composition (DEXA), and subjective markers (sleep depth, recovery, well-being). Paired pre-post measurement around cycles is the standard framework.

What are the long-term safety considerations?

Long-term safety data for most peptide compounds is limited to a small number of well-studied molecules with multi-decade clinical observation. For most others, the long-term framework relies on mechanism-based risk assessment plus accumulating clinical experience. Cycle-based dosing and periodic re-evaluation are appropriate for compounds without 10+ year human safety data.

What is the mechanism of action of DSIP?

Mechanism remains incompletely characterised. Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier. For healthspan and biological-age applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Mechanism remains incompletely characterised. The longevity / hallmarks of aging interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What route should I use for DSIP?

DSIP is delivered by subq/intranasal. The intranasal route is preferred for compounds targeting the central nervous system because it bypasses the BBB via the olfactory pathway. The choice depends on target system and convenience.

Clinical Protocol

Start a DSIP Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified DSIP and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: 848 Da
Sequence length: 9 aa
Half-life: ~7 min plasma; CNS effects longer
WADA: Not on prohibited list
FDA: Unapproved
Research: Preclinical + small human series

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for DSIP unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for DSIP

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised